Pharmacology of Iron Transport

被引:25
作者
Byrne, Shaina L. [1 ]
Krishnamurthy, Divya [1 ]
Wessling-Resnick, Marianne [1 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA
来源
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 | 2013年 / 53卷
关键词
hepcidin; hemochromatosis; transferrin; DMT1; NTBI; CELL LUNG-CANCER; PYRIDOXAL ISONICOTINOYL HYDRAZONE; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP; AMYLOID PRECURSOR PROTEIN; TRANSFERRIN-BOUND IRON; RIBONUCLEOTIDE REDUCTASE INHIBITOR; RECEPTOR-MEDIATED ENDOCYTOSIS; DIVALENT METAL TRANSPORTER-1; SMALL-MOLECULE INHIBITORS; FREE-RADICAL REACTIONS;
D O I
10.1146/annurev-pharmtox-010611-134648
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Elucidating the molecular basis for the regulation of iron uptake, storage, and distribution is necessary to understand iron homeostasis. Pharmacological tools are emerging to identify and distinguish among different iron transport pathways. Stimulatory or inhibitory small molecules with effects on iron uptake can help characterize the mechanistic elements of iron transport and the roles of the transporters involved in these processes. In particular, iron chelators can serve as potential pharmacological tools to alleviate diseases of iron overload. This review focuses on the pharmacology of iron transport, introducing iron transport membrane proteins and known inhibitors.
引用
收藏
页码:17 / 36
页数:20
相关论文
共 173 条
  • [1] A novel mammalian iron-regulated protein involved in intracellular iron metabolism
    Abboud, S
    Haile, DJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (26) : 19906 - 19912
  • [2] Role of TRP Channels in the Regulation of the Endosomal Pathway
    Abe, Ken
    Puertollano, Rosa
    [J]. PHYSIOLOGY, 2011, 26 (01) : 14 - 22
  • [3] IRON TRANSPORT AND STORAGE PROTEINS
    AISEN, P
    LISTOWSKY, I
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1980, 49 : 357 - 393
  • [4] Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy
    Andreassen, CN
    Gran, C
    Lindegaard, JC
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (01) : 62 - 72
  • [5] Evaluation of new iron chelators and their therapeutic potential
    Aouad, F
    Florence, A
    Zhang, Y
    Collins, F
    Henry, C
    Ward, RJ
    Crichton, RR
    [J]. INORGANICA CHIMICA ACTA, 2002, 339 : 470 - 480
  • [6] A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
    Attia, Steven
    Kolesar, Jill
    Mahoney, Michelle R.
    Pitot, Henry C.
    Laheru, Daniel
    Heun, James
    Huang, Wei
    Eickhoff, Jens
    Erlichman, Charles
    Holen, Kyle D.
    [J]. INVESTIGATIONAL NEW DRUGS, 2008, 26 (04) : 369 - 379
  • [7] Novel drug targets based on metallobiology of Alzheimer's disease
    Bandyopadhyay, Sanghamitra
    Huang, Xudong
    Lahiri, Debomoy K.
    Rogers, Jack T.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (11) : 1177 - 1197
  • [8] Bao GH, 2010, NAT CHEM BIOL, V6, P602, DOI [10.1038/nchembio.402, 10.1038/NCHEMBIO.402]
  • [9] A NON-TRANSFERRIN-BOUND SERUM IRON IN IDIOPATHIC HEMOCHROMATOSIS
    BATEY, RG
    FONG, PLC
    SHAMIR, S
    SHERLOCK, S
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1980, 25 (05) : 340 - 346
  • [10] Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload
    Beaumont, C
    Delaunay, J
    Hetet, G
    Grandchamp, B
    de Montalembert, M
    Tchernia, G
    [J]. BLOOD, 2006, 107 (10) : 4168 - 4170